Literature DB >> 8494335

Okadaic acid induces hyperphosphorylated forms of tau protein in human brain slices.

K A Harris1, G A Oyler, G M Doolittle, I Vincent, R A Lehman, R L Kincaid, M L Billingsley.   

Abstract

Hyperphosphorylated forms of the microtubule-associated protein tau are components of the paired helical filaments (PHFs) seen in patients with Alzheimer's disease. Slices of human lateral temporal cortex were obtained from tissues removed incidental to resections for intractable hippocampal epilepsy. Tau phosphorylation in temporal lobe slices was determined using mobility shifts after sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunodetection with the monoclonal antibodies Alz-50, 5E2, and Tau-1. The results indicate that tau phosphorylation was altered in a dose-dependent manner by the phosphatase inhibitor okadaic acid, but not by N-methyl-D-aspartate, quisqualate, or kainate. The slowest mobility forms of tau, termed "PHF-like tau," produced by okadaic acid treatment were dephosphorylated by purified protein phosphatase 2B (calcineurin). Formation of PHF-like tau peptides was blocked by KN-62, 1[N,O-bis(1,5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, an inhibitor of Ca2+/calmodulin-dependent protein kinase II. The protein kinase inhibitor staurosporine also prevented formation of PHF-like tau. These data suggest that phosphorylation of tau is regulated by Ca(2+)-dependent protein kinases and okadaic acid-sensitive protein phosphatases, alterations of which may be implicated in the pathogenesis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494335     DOI: 10.1002/ana.410330113

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

1.  Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases.

Authors:  L Y Cheng; J Z Wang; C X Gong; J J Pei; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

Review 2.  Neurotoxic and synaptic effects of okadaic acid, an inhibitor of protein phosphatases.

Authors:  R Tapia; F Peña; C Arias
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

3.  A spatial gradient of tau protein phosphorylation in nascent axons.

Authors:  J W Mandell; G A Banker
Journal:  J Neurosci       Date:  1996-09-15       Impact factor: 6.167

4.  The absence of a major Ca2+ signaling pathway in GABAergic neurons of the hippocampus.

Authors:  A Sík; N Hájos; A Gulácsi; I Mody; T F Freund
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

Review 5.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

Review 6.  Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.

Authors:  Laura J Blair; Jonathan J Sabbagh; Chad A Dickey
Journal:  Expert Opin Ther Targets       Date:  2014-07-29       Impact factor: 6.902

Review 7.  Kainic acid-mediated excitotoxicity as a model for neurodegeneration.

Authors:  Qun Wang; Sue Yu; Agnes Simonyi; Grace Y Sun; Albert Y Sun
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 8.  Paired helical filament tau in Alzheimer's disease. The kinase connection.

Authors:  J Q Trojanowski; V M Lee
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

9.  Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase-dependent mechanism.

Authors:  E Rundén; P O Seglen; F M Haug; O P Ottersen; T Wieloch; M Shamloo; J H Laake
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

Review 10.  Tau and axonopathy in neurodegenerative disorders.

Authors:  Makoto Higuchi; Virginia M Y Lee; John Q Trojanowski
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.